- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States
The independent financial analyst theScreener just lowered the general evaluation of IMMUNIC INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date January 24, 2020, the closing price was USD 8.21 and its target price was estimated at USD 2.13.